Microbot MedicalMBOT
MBOT
About: Microbot Medical Inc is a clinical-stage medical device company specializing in the research, design and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. It is focused on leveraging its robotic technologies to redefine surgical robotics while improving surgical outcomes for patients. Using its LIBERTY technological platform, the company is developing the first-ever fully disposable robot for various endovascular interventional procedures.
Employees: 22
0
Funds holding %
of 7,310 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,800% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 1
1,641% more call options, than puts
Call options by funds: $888K | Put options by funds: $51K
163% more capital invested
Capital invested by funds: $1.24M [Q4 2024] → $3.26M (+$2.02M) [Q1 2025]
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
14% more funds holding
Funds holding: 37 [Q4 2024] → 42 (+5) [Q1 2025]
0.31% less ownership
Funds ownership: 6.52% [Q4 2024] → 6.21% (-0.31%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$9
246%
upside
Avg. target
$9
246%
upside
High target
$9
246%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 246%upside $9 | Buy Reiterated | 10 Apr 2025 |
Financial journalist opinion
Based on 5 articles about MBOT published over the past 30 days
Neutral
GlobeNewsWire
5 days ago
Microbot Medical® Added to the Russell Microcap® Index
Automatic inclusion in the appropriate growth and value style indexes Automatic inclusion in the appropriate growth and value style indexes
Neutral
GlobeNewsWire
2 weeks ago
Microbot Medical Strengthens Global IP Portfolio with Newly Granted Patent in China
HINGHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, announced that it has been granted a critical patent in China by the China National Intellectual Property Administration (CNIPA), a key step in the Company's global IP expansion strategy.
Positive
Zacks Investment Research
3 weeks ago
Microbot Medical (MBOT) Upgraded to Buy: What Does It Mean for the Stock?
Microbot Medical (MBOT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
GlobeNewsWire
3 weeks ago
Microbot Medical Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of its LIBERTY® Endovascular Robotic System
HINGHAM, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, today announced the continued expansion of its commercial team in preparation for the anticipated U.S. launch of the LIBERTY System, which is projected during the third quarter of 2025.
Neutral
GlobeNewsWire
4 weeks ago
Microbot Medical Selected for Preliminary Inclusion to Russell Microcap® Index
HINGHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it has been selected for inclusion in the preliminary list of additions to the Russell Microcap® Index, as published by FTSE Russell on Friday, May 23, 2025. The newly reconstituted indexes are expected to take effect after U.S. market close on Friday, June 27, 2025, and be part of the 2025 Russell indexes reconstitution when the U.S. market opens on Monday, June 30, 2025.
Neutral
GlobeNewsWire
2 months ago
Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers
The addition of a seasoned VP of Marketing compliments the recent hiring of the Company's VP of Sales to establish its commercialization readiness infrastructure
Neutral
GlobeNewsWire
2 months ago
Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System
Successful robotic navigation was achieved in every case and met the primary endpoint of the study LIBERTY ® showed a 92% reduction in radiation exposure with no adverse events reported HINGHAM, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting.
Neutral
GlobeNewsWire
3 months ago
REMINDER: Microbot Medical Announces Data from the Company's ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting
Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter
Neutral
GlobeNewsWire
4 months ago
Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System
Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical which was Acquired by Stryker Corporation Earlier This Year
Neutral
GlobeNewsWire
4 months ago
Robotic Telesurgery Data from Collaboration with Corewell Health™ Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting
BRAINTREE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced its collaboration with Corewell Health™ has reached another meaningful milestone.
Charts implemented using Lightweight Charts™